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Background: A rare syndrome of watery diarrhea, hypokalemia and achlorhydria (WDHA) is usually caused by
pancreatic endocrine tumors that secrete excessive vasoactive intestinal polypeptide (VIP). Here we report a rare
case of WDHA caused by a pheochromocytoma.
Case presentation: A 45-year old male presented with persistent and progressive watery diarrhea for half a year,
and was treated with dialysis due to azotemia, hypokalemia, hypercalcemia and metabolic acidosis. A right adrenal
mass was found by ultrasonography, and Positron Emission Tomography-Computed Tomography (PET-CT) showed
the tumor was hyper-metabolic. Levels of plasma normetanephrine (NMN) and serum chromogranin A (CgA) were
significantly elevated. Immunohistochemistry analysis of the adrenal tumor was strongly positive for CgA, synaptophysin
and VIP. The patient fully recovered from WDHA syndrome soon after surgery, as reflected in that diarrhea stopped,
levels of plasma NMN, serum CgA, and electrolytes returned to normal thus no dialysis was needed. The patient
remained disease free in a 12-months follow-up period.
Conclusion: We report an extremely rare case of pheochromocytoma causing WDHA syndrome and uremia, which
the patient completely recovered from after tumor resection.
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Vasoactive intestinal peptide (VIP) is a 28-amnio acid
peptide that may cause secretory diarrhea when over-
produced by activating adenylate cyclase. A rare syn-
drome of watery diarrhea associated with hypokalemia
and achlorhydria (WDHA) due to hypersecretion of VIP
was described initially by Verner and Morrison in 1958
[1]. This syndrome is usually associated with pancre-
atic endocrine tumors (VIPomas), with only a few
exceptions. In this report, we describe a case of WDHA
caused by a VIP-positive pheochromocytoma. Surgical
resection of the tumor relieved all the symptoms and
normalized all the relevant biochemical characteristics
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A 45-year old man presented with persistent and
progressive watery diarrhea for half a year. He was ini-
tially admitted to a local hospital because he suddenly
lost consciousness, during which his blood pressure was
unmeasurable. Emergency lab tests revealed elevated
white blood cell count (WBC 21.4 × 109/L, N 86.4%),
hypercreatinemia (Cr 647umol/L) and hypokalemia
(K 2.9 mmol/L). Arterial blood gas tests indicated metabolic
acidosis and hypoxia (pH 7.16, HCO3 10 mmol/L, PO2
70%). He was intubated, maintained on hemodialysis and
treated with fluid and antibiotics intravenously. After his
condition improved, he was transferred to our hospital for
further diagnosis and treatment.
On admission, his blood pressure (BP) was around
90/55 mmHg, and heart rate (HR) was around 100 bpm.
The diarrhea and dehydration were so severe that daily
intravenous infusion of 10000 ml fluid could barely main-
tain his BP and HR stable. Anuria persisted with an
elevated level of serum Cr (Table 1). As such, the patienttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,









Cr (umol/L) 562 78 76 44-115
K + (mmol/L) 2.8 3.6 4.8 3.5-5.3
Ca2 + (mmol/L) 3.11 2.03 2.42 2.15-2.55
Albumin (g/L) 29 28 47 40-55
PTH (pg/ml) 8.7 52.5 55.3 15-65
Osteocalcin (ng/ml) 73.4 33.6 30.7 6-24.7
β-CTX (ng/ml) >6.0 3.05 0.46 0.04-0.78
P1NP (ng/ml) 150.9 305.4 133.8 9.1-76.2
Calcitonin (pg/ml) 128.0 3.4 <2 <8.4
CgA (ng/ml) >740 207.7 86.2 27-94
MN (pg/ml) 169.1 35.6 33.6 <96.6
NMN (pg/ml) 9554.1 79.6 51.1 <163
Serum electrolytes and hormones were measured before surgery, one week
after surgery and six months later.
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diarrhea responded poorly to the treatment with diosmec-
tite, loperamide or octreotide. Routine lab tests revealed
severe hypokalemia and hypercalcemia (Table 1). Bone
markers including osteocalcin, beta-CTX and P1NP were
all elevated (Table 1), suggesting a high bone turnover rate.
PTH was suppressed while calcitonin was elevated (Table 1).
The elevated calcitonin lead to the identification of a thy-
roid nodule at the left lobe by ultrasound. An abdominal
ultrasound identified a mass in the right adrenal region.
Plasma Normetanephrine (NMN) and metanephrine (MN)
were 9554.1 pg/ml and 169.1 pg/ml, respectively. Serum
chromogranin A (CgA) was beyond the detection range
(>740 ng/ml), and neuron specific enolase (NSE) normal
(14.8 ng/ml). A PET-CT scan revealed a 7.5 × 6.1 cm hyper-
metabolic adrenal mass, whose SUV(max) was 5.41. Several
hypodense areas showing no glucose metabolism were
found at the central part of the mass, suggesting necrosis
(Figure 1). A hypodense lesion, in size of 1.48 × 0.97 cm,
was identified at the left lobe of the thyroid gland with a
SUV(max) of 2.4.
The patient underwent a combined surgery, which
removed the adrenal mass and the left lobe of the
thyroid gland simultaneously. The surgery was com-
pleted uneventfully. The patient’s BP and HR were stable
during the resection of a 9 × 8 × 5 cm adrenal mass. The
gross and microscopic appearance was the typical
feature of pheochromocytoma, whereas the thyroid
nodule appeared to be a benign adenoma. There was no
evidence of medullary thyroid cancer.
After surgery, the patient’s symptoms relieved rapidly.
Diarrhea stopped soon after surgery. Moreover, his daily
urine increased gradually and serum Cr also lowered into a
normal range without dialysis. Plasma NMN, serum PTH,calcitonin and electrolytes all were back to normal (Table 1).
Osteocalcin and beta-CTX lowered significantly, while
P1NP increased significantly (Table 1). Two weeks after
surgery, the patient recovered completely and was
discharged. Six months after surgery, a comprehensive
follow-up check revealed no abnormalities in the rele-
vant biochemical makers, except for a slightly high
P1NP (Table 1). Till now, the patient has been followed
for one year, showing no sign of recurrence.
Discussion
The first case of pheochromocytoma that causes WDHA
syndrome was described by Loehry in 1975 [2]. Based on
histology, there are two subtypes for these VIP-secreting
pheochromocytomas: the composite form (mixed pheo-
chromocytoma and ganglioneuroma) and the classic form
(pheochromocytoma only). The latter causing WDHA
syndrome has been reported in only 11 cases to date
[2-12], including the current one. The mean age of the 11
patients was 49 years old (ranging from 28 to 84 years). A
preference for female was noted, since only 2 patients
were men, including the current case. It is noteworthy that
severe azotemia and uremia presented in our case have
never been described in previous cases. Octreotide is a
recommended medication for treatment of WDHA
syndrome as it improves diarrhea in >75% of patients with
VIPomas and reduces VIP secretion [13]. Despite being
the recommended medication, VIP-secreting pheochro-
mocytomas had a relatively poor response to octreotide, a
finding consistent with previous reports, thus implying
the lack of somatostatin receptors in these VIP-containing
tumor cells [8].
In the current case, the tumor appeared as a well-
encapsuled brownish mass with a variegated cut surface
and necrotic areas, showing a typical feature of pheochro-
mocytoma. Histologically, adipose and fibrous tissues infil-
trated by tumor cells were observed (Figure 2A). Almost all
tumor cells (100%) were strongly positive for synaptophysin
and CgA, and 40% of cells strongly positive for VIP.
The VIP positive cells were clustered and scattered
among the tumor cells (Figure 2B-D). Calcitonin stain-
ing was negative (data not shown). No ganglioneuroma
component was identified, ruling out the composite
form. According to the IHC staining, the current case
can be diagnosed as a VIP-secreting pheochromocy-
toma. Unfortunately, this was not confirmed by bio-
chemically measuring the secretion of VIP from the
tumor, because the assay is currently unavailable in
mainland China. It is noteworthy that no malignancy
was described in the previous 10 cases. However, the
present case showed infiltration of tumor cells into
adipose tissue, large areas of necrosis in the tumor and
intravascular tumor thrombi, suggesting a potential
malignant phenotype.
Figure 1 A PET-CT scan demonstrating a large, well defined adrenal mass. A large hyper-metabolic mass was located at the right adrenal re-
gion. The hypodense areas at the center indicated necrosis. Massive fluid collection could be found in the colon.
Jiang et al. BMC Cancer 2014, 14:553 Page 3 of 5
http://www.biomedcentral.com/1471-2407/14/553The effect of VIP on bone metabolism has not been
established, although it was reported that VIP recep-
tors are expressed by both osteoblasts and osteoclasts
[14,15]. The present case has provided the first clinical
evidence that VIPoma is associated with a dysfunction
of bone metabolism, as exemplified by the increase of
osteocalcin, P1NP and most significantly, beta-CTX
(Table 1). After surgery, beta-CTX subsided, and P1NP
rose significantly (Table 1), suggesting a shift from bone
resorption toward bone formation. It is very interesting tonote that another patient with VIPoma, who was diag-
nosed recently in our hospital, has shown a very similar
pattern of changes in bone metabolism before and after
surgery (Jiang et al., unpublished data). It has been
reported that WDHA syndrome is often accompanied
by hypercalcemia [13]. The current case showing a
dysfunction of bone metabolism suggests a direct
effect of VIP on osteoclasts, which should be consi-
dered as the underlying mechanism of hypercalcemia
in the patients with VIPoma.
Figure 2 Pathology slides of the resected specimen with different stains. A: Hematoxylin and eosin stained section of the adrenal
mass demonstrating adipose tissues infiltrated by tumor cells (×100). B: Immunohistochemical detection of synaptophysin in the tumor
cells (×100). C: Immunohistochemical detection of chromogranin A in the tumor cells (×100). D: Immunohistochemical detection of
VIP-positive cells (×200).
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lous recovery of renal function after surgical treatment.
To our knowledge, this is the first case of VIP-secreting
pheochromocytoma with such a high level of Cr that
hemodialysis was needed. In considering that the
diarrhea and dehydration lasted for several months, pre-
renal azotemia was suspected initially. As such, chances
for recovery would be slim. But after surgical removal of
the adrenal mass, serum Cr decreased dramatically
together with a gradual increase in urine volumes, and
dialysis was no longer needed. Another interesting
finding in this case is that, despite extremely high level
of NMN, the patient had no hypertensive symptoms.
Such a typical characteristic of pheochromocytoma was
probably masked by the vasodilative effect of VIP and
severe dehydration due to diarrhea.
Because both NMN and calcitonin were elevated, mul-
tiple endocrine neoplasia type 2 (MEN2) was suspected
in the initial diagnosis. Upon investigation, the patient
had no relevant family history and the histology of
thyroid specimen did not support the diagnosis of
MEN2. It should also be mentioned that NMN was
significantly elevated in the present case, whereas
pheochromocytomas in MEN2 typically produce epi-
nephrine, leading to elevated MN [16,17]. Moreover, a
fast screening of genomic DNA in our patient’s sample
failed to identify any common RET gene mutations.
We have also performed sequencing on the whole
coding region of RET using cDNA from thyroid tissues
of our patient, and no mutation was identified. Basedon these investigations, along with the patient’s clinical
manifestations, we could exclude the possibility of
MEN2. So far, the only genetic manifestation of pheo-
chromocytoma associated with WDHA syndrome was
found being a NF1 gene mutation, with two cases
reported in the literature [8,18]. A pheochromocytoma
secreting calcitonin has been previously reported in a
MEN2A patient bearing a triple RET gene mutation
[19]. Yet the reason for the elevated calcitonin in this
case remains unknow, as the IHC for calcitonin was
negative in both pheochromocytoma and the thyroid
nodule of the patient.Conclusions
In conclusion, the current report describes a very rare
case of WDHA syndrome caused by a VIP-positive
pheochromocytoma. It is also the first case of WDHA
that progressed to uremia relying on hemodialysis, and
yet recovered completely after surgical removal of the
pheochromocytoma. In addition, this was also reported
for the first time that a VIP-positive pheochromocy-
toma had significant effects on bone metabolism in the
patient.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
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